Evaluating AR1001 as Monotherapy from a Phase 2 Study in Mild to Moderate Alzheimer’s Disease Patients

The subgroup analysis of participants on AR1001 30 mg without concomitant AD medication suggests potential for AR1001 as a monotherapy for the treatment of Alzheimer's disease.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70859_107781
Primary Topic
Phosphodiesterase function and regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluating AR1001 as Monotherapy from a Phase 2 Study in Mild to Moderate Alzheimer’s Disease Patients

Fred Kim, Jai Jun Choung, Tianyang Xi, S Kim et al.
Alzheimer s & Dementia
Phosphodiesterase function and regulation
article

Evaluating AR1001 as Monotherapy from a Phase 2 Study in Mild to Moderate Alzheimer’s Disease Patients

Fred Kim, Jai Jun Choung, Tianyang Xi, S Kim, Han Joo Lee, James Arthur Rock
article en

Abstract

The subgroup analysis of participants on AR1001 30 mg without concomitant AD medication suggests potential for AR1001 as a monotherapy for the treatment of Alzheimer's disease.

Alzheimer s & DementiaVol. 21(S5)
Autism Research Institute (US), Seoul National University Bundang Hospital (KR), Adone (South Korea) (KR)
Good health and well-being
Openalex Percentile: Top 36%
Phosphodiesterase function and regulation
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.